BioCentury
ARTICLE | Company News

Biovail acquires Aventis cardiovascular product line

January 2, 2001 8:00 AM UTC

Biovail (BVF; TSE:BVF) will pay $409.5 million for North American rights to AVE 's Cardizem calcium channel blockers. BVF paid $239.5 million at the close of the deal with the balance to be paid equal...